You are entering otezlapro.com, intended for US audiences only. Click a link below to certify that you are a licensed healthcare professional.
Please see Important Safety Information presented throughout this site and Full Prescribing Information.
Otezla significantly increased PASI-75 response (n = 562) at week 16 (primary endpoint) vs placebo (n = 282) (33% vs 5%; P < 0.0001)
See study design
Indications & Important Safety Information
Please click here for Full Prescribing Information.
Do you wish to leave this site?
8 out of 10
commercially insured lives in the US have preferred access with no biologic step required for Otezla® (apremilast)1